Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.
作者信息
Okeleji Olayinka, McCall David, Gibson Amber, Garcia Miriam B, Nunez Cesar, Roth Michael, Connors Jeremy, Petropoulos Demetrios, Tewari Priti, Cuglievan Branko, Sheikh Irtiza N
机构信息
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Leukemia Section, Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
出版信息
Blood Adv. 2025 Apr 22;9(8):1988-1990. doi: 10.1182/bloodadvances.2024015527.
Abstract
摘要
相似文献
1
Post transplant maintenance therapy with newly FDA-approved revumenib for high-risk KMT2Ar acute leukemia.采用新获美国食品药品监督管理局批准的瑞武尼布对高危KMT2Ar急性白血病进行移植后维持治疗。
Blood Adv. 2025 Apr 22;9(8):1988-1990. doi: 10.1182/bloodadvances.2024015527.
2
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).使用瑞武尼布抑制Menin治疗重排的复发或难治性急性白血病（AUGMENT-101）。
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
3
Menin Inhibitors: New Targeted Therapies for Specific Genetic Subtypes of Difficult-to-Treat Acute Leukemias.Menin抑制剂：针对难治性急性白血病特定基因亚型的新型靶向疗法。
Cancers (Basel). 2025 Jan 4;17(1):142. doi: 10.3390/cancers17010142.
4
Revumenib: First Approval.瑞武单抗：首次获批。
Drugs. 2025 Apr;85(4):577-583. doi: 10.1007/s40265-025-02161-5.
5
Synergistic Effects of the RAR Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation.维甲酸受体激动剂他米巴罗汀与Menin抑制剂瑞武尼布对伴有KMT2A重排或NPM1突变的急性髓系白血病细胞的协同作用
Cancers (Basel). 2024 Mar 28;16(7):1311. doi: 10.3390/cancers16071311.
6
Predictors of outcomes in adults with acute myeloid leukemia and KMT2A rearrangements.伴有 KMT2A 重排的成人急性髓系白血病的预后预测因素。
Blood Cancer J. 2021 Sep 29;11(9):162. doi: 10.1038/s41408-021-00557-6.
7
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study.使用瑞武尼布抑制Menin治疗NPM1突变的复发或难治性急性髓系白血病：AUGMENT-101研究
Blood. 2025 May 7. doi: 10.1182/blood.2025028357.
8
An Ultra-Fast Validated Green UPLC-MS/MS Approach for Assessing Revumenib in Human Liver Microsomes: In Vitro Absorption, Distribution, Metabolism, and Excretion and Metabolic Stability Evaluation.一种用于评估人肝微粒体中瑞武尼布的超快速验证绿色超高效液相色谱-串联质谱法：体外吸收、分布、代谢、排泄及代谢稳定性评估
Medicina (Kaunas). 2024 Nov 21;60(12):1914. doi: 10.3390/medicina60121914.
9
Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.蛋白酶体抑制作用靶向急性淋巴细胞白血病中的 KMT2A 转录复合物。
Nat Commun. 2023 Feb 13;14(1):809. doi: 10.1038/s41467-023-36370-x.
10
Revumenib: a new era in acute leukemia treatment.瑞武利布：急性白血病治疗的新时代。
Trends Cancer. 2025 Feb;11(2):81-83. doi: 10.1016/j.trecan.2025.01.006. Epub 2025 Jan 24.
本文引用的文献
1
Rearrangements in Leukemias: Molecular Aspects and Therapeutic Perspectives.白血病中的重排：分子方面和治疗前景。
Int J Mol Sci. 2024 Aug 20;25(16):9023. doi: 10.3390/ijms25169023.
2
Menin inhibitors in pediatric acute leukemia: a comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community.儿童急性白血病中的 Menin 抑制剂：全面综述及建议，旨在与成人白血病和国际社会合作加速进展。
Leukemia. 2024 Oct;38(10):2073-2084. doi: 10.1038/s41375-024-02368-7. Epub 2024 Aug 23.
3
Menin Inhibition With Revumenib for -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).使用瑞武尼布抑制Menin治疗重排的复发或难治性急性白血病（AUGMENT-101）。
J Clin Oncol. 2025 Jan;43(1):75-84. doi: 10.1200/JCO.24.00826. Epub 2024 Aug 9.
4
Post-Transplant Maintenance Therapy in Acute Myeloid Leukemia.急性髓系白血病移植后的维持治疗
Cancers (Basel). 2024 May 26;16(11):2015. doi: 10.3390/cancers16112015.
5
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia.2024年Menin抑制剂最新进展：针对KMT2A重排和NPM1突变急性髓系白血病的新型靶向药物
Hematol Rep. 2024 Apr 18;16(2):244-254. doi: 10.3390/hematolrep16020024.
6
Optimized cytogenetic risk-group stratification of KMT2A-rearranged pediatric acute myeloid leukemia.优化 KMT2A 重排型小儿急性髓系白血病的细胞遗传学危险度分组。
Blood Adv. 2024 Jun 25;8(12):3200-3213. doi: 10.1182/bloodadvances.2023011771.
7
Further validation of poor prognosis for pediatric -rearranged leukemia and the need for rapid integration of targeted therapies for these patients.小儿重排白血病预后不良的进一步验证以及这些患者快速纳入靶向治疗的必要性。
Transl Pediatr. 2024 Feb 29;13(2):370-375. doi: 10.21037/tp-23-567. Epub 2024 Feb 27.
8
Small Molecule Menin Inhibitors: Novel Therapeutic Agents Targeting Acute Myeloid Leukemia with KMT2A Rearrangement or NPM1 Mutation.小分子Menin抑制剂：靶向具有KMT2A重排或NPM1突变的急性髓系白血病的新型治疗药物。
Oncol Ther. 2024 Mar;12(1):57-72. doi: 10.1007/s40487-024-00262-x. Epub 2024 Feb 1.
9
Therapeutic targeting in pediatric acute myeloid leukemia with aberrant HOX/MEIS1 expression.治疗靶向治疗伴有异常 HOX/MEIS1 表达的小儿急性髓系白血病。
Eur J Med Genet. 2023 Dec;66(12):104869. doi: 10.1016/j.ejmg.2023.104869. Epub 2023 Oct 29.
10
Outcomes of Childhood Noninfant Acute Lymphoblastic Leukemia With 11q23/ Rearrangements in a Modern Therapy Era: A Retrospective International Study.现代治疗时代伴有 11q23/重排的儿童非婴儿急性淋巴细胞白血病的结局：一项回顾性国际研究。
J Clin Oncol. 2023 Mar 1;41(7):1404-1422. doi: 10.1200/JCO.22.01297. Epub 2022 Oct 18.
Zotero 插件